LakeShore Biopharma Co Ltd. (LSB)

Market Cap	107.27M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	188.33M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,325
Open	0.590
Previous Close	0.608
Day's Range	0.550 - 0.600
52-Week Range	0.350 - 1.500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2024

About LSB

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 773
• Stock Exchange: NASDAQ
• Ticker Symbol: LSB

Financial Performance

In 2022, LSB's revenue was 687.20 million, an increase of 36.63% compared to the previous year's 502.95 million. Losses were -421.46 million, 14.7% more than in 2021.

Financial numbers in CNY